Xenon Pharmaceuticals 미래 성장

Future 기준 확인 2/6

Xenon Pharmaceuticals (는) 각각 연간 12.6% 및 78.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 15.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -54.8% 로 예상됩니다.

주요 정보

12.6%

수익 성장률

15.5%

EPS 성장률

Biotechs 수익 성장	27.6%
매출 성장률	78.8%
향후 자기자본 수익률	-54.8%
애널리스트 커버리지	Good
마지막 업데이트	18 Dec 2024

최근 미래 성장 업데이트

Recent updates

Estimating The Intrinsic Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Nov 25

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Oct 20

Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain

Aug 09

Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?

Aug 09

Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans

Jul 05

We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right

May 29

Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Apr 16

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Mar 12

Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'

Feb 08

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Oct 21

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Jun 22

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Feb 15

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Oct 27

Xenon started at outperform at Raymond James on experimental epilepsy drug

Oct 19

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate

Sep 22

Putting Xenon Pharmaceuticals Back In The Spotlight

Sep 06

Xenon initiated with Buy at BofA citing potential of anti-seizure drug

Aug 29

Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Jun 13

Sizing Up Xenon Pharmaceuticals

Dec 13

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Nov 12

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Aug 05

Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%

May 13

수익 및 매출 성장 예측

NasdaqGM:XENE - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	34	-349	-298	-285	13
12/31/2025	5	-295	-263	-248	16
12/31/2024	0	-240	-220	-183	16
9/30/2024	N/A	-213	-159	-157	N/A
6/30/2024	N/A	-199	-157	-154	N/A
3/31/2024	N/A	-189	-158	-154	N/A
12/31/2023	N/A	-182	-151	-145	N/A
9/30/2023	N/A	-176	-156	-148	N/A
6/30/2023	0	-165	-137	-131	N/A
3/31/2023	1	-148	-119	-114	N/A
12/31/2022	9	-126	-101	-98	N/A
9/30/2022	13	-113	-88	-86	N/A
6/30/2022	21	-91	-73	-71	N/A
3/31/2022	23	-83	-69	-67	N/A
12/31/2021	18	-81	-72	-70	N/A
9/30/2021	20	-66	-64	-62	N/A
6/30/2021	18	-59	-61	-58	N/A
3/31/2021	29	-37	-58	-56	N/A
12/31/2020	32	-29	-51	-48	N/A
9/30/2020	30	-28	-18	-15	N/A
6/30/2020	27	-28	-13	-11	N/A
3/31/2020	14	-38	-11	-9	N/A
12/31/2019	7	-42	-6	-5	N/A
9/30/2019	4	-39	-33	-32	N/A
6/30/2019	N/A	-44	-39	-38	N/A
3/31/2019	N/A	-42	-36	-35	N/A
12/31/2018	N/A	-34	-35	-35	N/A
9/30/2018	0	-34	-35	-34	N/A
6/30/2018	0	-27	N/A	-29	N/A
3/31/2018	0	-27	N/A	-30	N/A
12/31/2017	0	-31	N/A	-29	N/A
9/30/2017	1	-29	N/A	-27	N/A
6/30/2017	1	-29	N/A	-22	N/A
3/31/2017	1	-27	N/A	-21	N/A
12/31/2016	2	-23	N/A	-20	N/A
9/30/2016	5	-21	N/A	-20	N/A
6/30/2016	9	-17	N/A	-21	N/A
3/31/2016	12	-10	N/A	-17	N/A
12/31/2015	16	-16	N/A	-18	N/A
9/30/2015	17	-2	N/A	-16	N/A
6/30/2015	26	5	N/A	-5	N/A
3/31/2015	27	4	N/A	-4	N/A
12/31/2014	28	13	N/A	0	N/A
9/30/2014	29	6	N/A	1	N/A
6/30/2014	27	4	N/A	-1	N/A
3/31/2014	27	4	N/A	-1	N/A
12/31/2013	27	4	N/A	-3	N/A

애널리스트 미래 성장 예측

수입 대 저축률: XENE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: XENE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: XENE 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: XENE 의 수익(연간 78.8% ) US 시장( 9.1% 보다 빠르게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: XENE 의 수익(연간 78.8% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: XENE (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 16:39
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Xenon Pharmaceuticals Inc. 25 애널리스트 중 16 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Brian Skorney	Baird
Jason Matthew Gerberry	BofA Global Research
John Newman	Canaccord Genuity

Xenon Pharmaceuticals 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates decrease by 22%

Consensus revenue estimates decrease by 23%

Consensus revenue estimates fall by 19%

Consensus forecasts updated

Consensus forecasts updated

Price target increased to US$48.82

Recent updates

Xenon Pharmaceuticals Inc. to Showcase New Long-Term Azetukalner Data at AES 2024

Estimating The Intrinsic Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 12, 2024

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain

Is There An Opportunity With Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) 37% Undervaluation?

Xenon Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024

Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans

We Think The Compensation For Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) CEO Looks About Right

Xenon Pharmaceuticals Inc. Presents Data from Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder At the American Society of Clinical Psychopharmacology 2024 Annual Meeting

Xenon Pharmaceuticals Inc. to Report Q1, 2024 Results on May 09, 2024

Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Independent Director recently sold US$602k worth of stock

Xenon Pharmaceuticals Inc., Annual General Meeting, Jun 04, 2024

Xenon Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 29, 2024

Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'

Consensus revenue estimates decrease by 22%

Independent Director recently sold US$312k worth of stock

Independent Director notifies of intention to sell stock

Xenon Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $300.000013 million.

Xenon Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $300.000013 million.

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder (Mdd)

Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder (Mdd)

Consensus revenue estimates decrease by 23%

Xenon Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation

Xenon Pharmaceuticals Announces Publication of Results from Xen1101 Phase 2B "X-Tole" Clinical Trial in Peer-Reviewed Journal Article in Jama Neurology

Xenon Pharmaceuticals Inc. Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

High number of new directors

Lead Independent Director recently sold US$968k worth of stock

Consensus revenue estimates fall by 19%

First half 2023 earnings released: US$1.38 loss per share (vs US$0.87 loss in 1H 2022)

Xenon Pharmaceuticals Inc. Announces Board Appointments

Xenon Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 09, 2023

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Chairman of the Board recently sold US$4.2m worth of stock

President notifies of intention to sell stock

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.37 loss in 1Q 2022)

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely

Xenon Pharmaceuticals Inc. Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)

Independent Director recently sold US$71k worth of stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Xenon Pharmaceuticals Inc. Announces Appointment of Andrea Difabio as Chief Legal Officer and Corporate Secretary

Xenon Pharmaceuticals Inc. Announces Launch of XEN1101 Phase 3 Program with Initiation of X TOLE2 Clinical Trial in Patients with Focal Onset Seizures

Xenon Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022

Now 20% undervalued

We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth

Xenon started at outperform at Raymond James on experimental epilepsy drug

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate

Putting Xenon Pharmaceuticals Back In The Spotlight

Insider exercised options and sold US$2.5m worth of stock

Xenon initiated with Buy at BofA citing potential of anti-seizure drug

Chairman of the Board recently sold US$6.8m worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to US$48.82

Xenon Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022

Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program

Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA

Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price

Xenon Pharmaceuticals Inc. Announces Michael Hayden Will Not Stand for Re-Election as Member of Board

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as Treatment for Major Depressive Disorder

Executive Chairman recently sold US$734k worth of stock

Consensus forecasts updated